Tiverton Asset Management LLC Sells 1,716 Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART)

Share on StockTwits

Tiverton Asset Management LLC decreased its stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 21.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,126 shares of the life sciences company’s stock after selling 1,716 shares during the quarter. Tiverton Asset Management LLC’s holdings in Integra Lifesciences were worth $342,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new position in Integra Lifesciences during the 2nd quarter worth approximately $26,000. Quadrant Capital Group LLC boosted its position in shares of Integra Lifesciences by 223.0% during the first quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 446 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Integra Lifesciences by 120.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock valued at $129,000 after buying an additional 1,266 shares during the period. Stanley Laman Group Ltd. bought a new stake in shares of Integra Lifesciences in the 1st quarter valued at $223,000. Finally, Zions Bancorporation N.A. bought a new stake in shares of Integra Lifesciences in the 1st quarter valued at $229,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

IART has been the topic of several recent analyst reports. Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a report on Monday, September 2nd. BTIG Research set a $70.00 price objective on Integra Lifesciences and gave the company a “buy” rating in a research report on Wednesday, July 24th. Royal Bank of Canada set a $66.00 target price on Integra Lifesciences and gave the stock a “hold” rating in a research note on Friday, July 26th. ValuEngine downgraded shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. Finally, JMP Securities lifted their price target on shares of Integra Lifesciences to $75.00 in a research note on Thursday, July 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. Integra Lifesciences has an average rating of “Hold” and a consensus price target of $62.67.

IART traded up $0.53 on Wednesday, reaching $63.69. The company had a trading volume of 13,183 shares, compared to its average volume of 470,463. The stock has a market cap of $5.22 billion, a P/E ratio of 26.35, a P/E/G ratio of 1.92 and a beta of 1.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. Integra Lifesciences Holdings Corp has a fifty-two week low of $42.14 and a fifty-two week high of $66.41. The company’s fifty day moving average is $61.30 and its 200 day moving average is $55.04.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The company had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 earnings per share. On average, sell-side analysts expect that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current year.

In related news, COO Glenn Coleman sold 3,650 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $55.00, for a total value of $200,750.00. Following the sale, the chief operating officer now directly owns 25,160 shares of the company’s stock, valued at $1,383,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Richard E. Caruso sold 80,000 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $61.77, for a total value of $4,941,600.00. Following the completion of the sale, the insider now directly owns 134,134 shares in the company, valued at $8,285,457.18. The disclosure for this sale can be found here. Insiders sold a total of 362,322 shares of company stock valued at $22,039,086 over the last 90 days. 4.50% of the stock is currently owned by corporate insiders.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Earnings Reports

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.